
Healthcare · NSE / BSE
Incorporated in 2010, Nephrocare Health Services Ltd. provides comprehensive dialysis care through an extensive network of clinics across India and select international markets. As of March 31, 2025, the company operated 490 clinics—447 in India and 43 across the Philippines, Uzbekistan, and Nepal—including the world’s largest dialysis clinic in Uzbekistan. Nephrocare serves 269 cities across 21 states and 4 union territories, with nearly 77% of its centers located in tier II and III regions to improve access for underserved populations. In FY 2025, it treated 29,281 patients and delivered over 2.88 million dialysis sessions, representing about 10% of India’s dialysis patient base. The company managed 5,068 dialysis machines by March 2025, demonstrating consistent growth over prior years. Nephrocare has also partnered with leading hospital chains such as Max, Fortis Escorts, Care Hospitals, Wockhardt, Paras, CMRI, Jehangir Hospital, and Ruby Hall Clinic to operate in-house dialysis centers and enhance service reach.
Price Band
₹438 – ₹460
Issue Size
₹871 Cr
Lot Size
32 shares
GMP
+7.8%
Est. Listing
₹496
at current GMP
Subscribed
14.08x
overall
Open
10 Dec 2025
Close
12 Dec 2025
Allotment
15 Dec 2025
Refund
16 Dec 2025
Demat Credit
17 Dec 2025
Listing
17 Dec 2025
Last updated: 19 Oct 2026
Current Premium
Issue Price (Upper)
₹460
Band: ₹438 – ₹460
Estimated Listing Price
₹496
Upper price + GMP
Lot Size
32 shares
Min investment ₹14,720
Estimated Profit / Lot
₹1,152
32 × ₹36
Grey Market Premium trend
—
▲ 0 today
Updated 11 months ago
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 3 Dec 2025 | — | 0.0% | ₹460 |
| 4 Dec 2025 | — | 0.0% | ₹460 |
| 5 Dec 2025 | — | 0.0% | ₹460 |
| 6 Dec 2025 | — | 0.0% | ₹460 |
| 8 Dec 2025 | — | 0.0% | ₹460 |
| 9 Dec 2025 | — | 0.0% | ₹460 |
| 10 Dec 2025 | — | 0.0% | ₹460 |
| 11 Dec 2025 | +₹17.5 | 3.8% | ₹477.5 |
| 12 Dec 2025 | +₹31 | 6.7% | ₹491 |
| 12 Dec 2025 | +₹25 | 5.4% | ₹485 |
| 12 Dec 2025 | +₹22 | 4.8% | ₹482 |
| 13 Dec 2025 | +₹37 | 8.0% | ₹497 |
| 14 Dec 2025 | +₹32 | 7.0% | ₹492 |
| 15 Dec 2025 | +₹30 | 6.5% | ₹490 |
| 15 Dec 2025 | +₹34 | 7.4% | ₹494 |
| 15 Dec 2025 | +₹35 | 7.6% | ₹495 |
| 16 Dec 2025 | +₹43 | 9.3% | ₹503 |
| 16 Dec 2025 | +₹41 | 8.9% | ₹501 |
| 20 May 2026 | +₹36 | 7.8% | ₹496 |
GMP is unofficial market data. Not a guarantee of listing performance.
Nephrocare Health Services Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹871.05 Crores. The shares are offered at a price band of ₹438 to ₹460 per equity share on NSE and BSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 32 shares (approx. ₹14,720 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Kfin Technologies Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2025-12-17, while un-allotted funds or UPI block mandates will be released on 2025-12-16.
The latest grey market premium for Nephrocare Health Services Limited IPO is ₹36, which indicates an expected listing price of ₹496.
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.